NovoTTF-100A (NovoCure) therapy achieves encouraging long term survival time for Glioblastoma patients

Results from a Phase III EF-11 study comparing overall survival at two and three years after initiating therapy in patients with recurrent glioblastoma multiforme (GBM) treated with NovoTTF-100A therapy, from NovoCure, versus standard chemotherapy show they remain consistent with one-year survival data. With a median follow-up of 39 months, overall survival in the TTF group compared to the chemotherapy group at two and three years was 9% vs. 7% and 8% vs. 1%, respectively. The study also showed trends in favor of TTF compared to chemotherapy in PFS6 (21.4% vs. 15.2%, respectively) and radiological response rates (14.0% vs. 9.6%, respectively). Finally, patients in the TTF group had many less grade 2 or higher side effects and their quality of life was better than patients receiving chemotherapy. Results were presented by Eric T. Wong, Co-Director, Brain Tumor Center, Beth Israel Deaconess Medical Center in Boston. at the Scientific Meeting of the Society for NeuroOncology.